Compare EPR Properties (EPR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs State Street SPDR S&P Biotech ETF — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.4× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EPR | XBI | |
|---|---|---|
Market Cap | $4.17B | $10.11B |
Volume | 992,716 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $64.32 | $169.55 |
52-Week Low | $48.71 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $7.68B | — |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.74, up 1.22% today, with a bearish technical signal despite oversold RSI readings. The REIT reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Fundamentals show strong profitability with a 37.66% net income margin and a 6.5% dividend yield, supported by $421M in operating cash flow for 2025. Recent news highlights its appeal as a high-yield monthly dividend stock for retirees, with diversification into theme parks and fitness.
The outlook is cautiously optimistic, with a consensus price target of $65.50 implying 20% upside, though technical weakness and a projected net cash flow decline in 2026 pose risks. Investment opportunities include undervaluation relative to peers and resilient tenant performance, while risks involve interest rate sensitivity and execution of diversification strategy amid economic uncertainty.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
